human | Q5 |
P6178 | Dimensions author ID | 0671406106.09 |
P496 | ORCID iD | 0000-0002-6792-4748 |
P1153 | Scopus author ID | 6701762464 |
P108 | employer | University of the Witwatersrand Faculty of Health Sciences | Q5428977 |
FIND, the global alliance for diagnostics | Q5474445 | ||
National Health Laboratory Service | Q17052573 | ||
P734 | family name | Carmona | Q16865386 |
Carmona | Q16865386 | ||
Carmona | Q16865386 | ||
P735 | given name | Sergio | Q18061657 |
Sergio | Q18061657 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q42234063 | A serious parvovirus B19 genotype 2 infection not detected in a commercial PCR assay |
Q46329054 | Absence of Acanthocytosis in Huntington's Disease-like 2: A Prospective Comparison with Huntington's Disease |
Q52641448 | Adult antiretroviral therapy guidelines 2017. |
Q93355465 | Appropriate clinical use of darunavir 800 mg |
Q51736507 | Collaborative care for the detection and management of depression among adults receiving antiretroviral therapy in South Africa: study protocol for the CobALT randomised controlled trial. |
Q40104085 | Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation |
Q35331479 | Design and implementation of an external quality assessment program for HIV viral load measurements using dried blood spots |
Q38852072 | Early Diagnosis of HIV Infection in Infants - One Caribbean and Six Sub-Saharan African Countries, 2011-2015. |
Q46278917 | Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. |
Q55205473 | Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa. |
Q36033368 | Exploiting the RNA interference pathway to counter hepatitis B virus replication. |
Q40064365 | Field Evaluation of Performance of Alere and Cepheid Qualitative HIV Assays for Pediatric Point-of-Care Testing in an Academic Hospital in Soweto, South Africa |
Q41919022 | HIV drug resistance in African infants and young children newly diagnosed with HIV: a multicounty analysis |
Q39109215 | HIV viral load scale-up: multiple interventions to meet the HIV treatment cascade. |
Q28271593 | HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing |
Q39360243 | HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. |
Q28543358 | High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa |
Q28538692 | High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen |
Q37040586 | Improved Sensitivity of a Dual-Target HIV-1 Qualitative Test for Plasma and Dried Blood Spots |
Q56948059 | Improving Linkage to HIV Care Through Mobile Phone Apps: Randomized Controlled Trial |
Q64085811 | Improving Linkage to and Retention in Care in Newly Diagnosed HIV-Positive Patients Using Smartphones in South Africa: Randomized Controlled Trial |
Q31155083 | Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study |
Q35455196 | Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa |
Q34409299 | Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort |
Q38380464 | Mobility and Clinic Switching Among Postpartum Women Considered Lost to HIV Care in South Africa |
Q28554729 | Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey |
Q33603586 | Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration |
Q42576460 | Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. |
Q52669148 | Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort. |
Q39125858 | Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. |
Q38851986 | Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016. |
Q53763317 | Recommendations for the management of indeterminate HIV PCR results within South Africa's early infant diagnosis programme. |
Q38371483 | Scale-up of Early Infant HIV Diagnosis and Improving Access to Pediatric HIV Care in Global Plan Countries: Past and Future Perspectives |
Q39165543 | Scale-up of HIV Viral Load Monitoring--Seven Sub-Saharan African Countries |
Q91386119 | Separation of Plasma from Whole Blood by Use of the cobas Plasma Separation Card: a Compelling Alternative to Dried Blood Spots for Quantification of HIV-1 Viral Load |
Q40278977 | Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. |
Q44727822 | Simplified ELISA for detecting antibodies to recombinant fusion proteins. |
Q52641450 | South African HIV self-testing policy and guidance considerations. |
Q93355458 | Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy |
Q39044352 | The cobas® 6800/8800 System: a new era of automation in molecular diagnostics |
Q36414140 | Use of a prequalification panel for rapid scale-up of high-throughput HIV viral load testing. |
Q37610648 | Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa |
Q89876272 | Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study |
Search more.